Video: Ticagrelor (BRILINTA(TM)) Demonstrated Greater Efficacy Over Clopidogrel in the Most Urgent Clinical Setting: Patients with ST-Segment Elevation Myocardial Infarction and Planned Percutaneous Coronary Intervention (PCI)

ORLANDO, Fla., Nov. 15 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced results of a PLATO sub-analysis in the most serious type of Acute Coronary Syndrome (ACS) patients, those with ST Segment Elevation Myocardial Infarction (STEMI). In this setting, ST segment elevation indicates total obstruction of a coronary artery which warrants emergency surgery with angioplasty, a procedure termed primary Percutaneous Coronary Intervention or "PCI," in order to restore flow, salvage the heart muscle (myocardium) from infarction and reduce mortality.